Tadao Akizawa1, Yusuke Yamaguchi2, Tetsuro Otsuka3, Michael Reusch4. 1. Division of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan, akizawa@med.showa-u.ac.jp. 2. Data Science, Development, Astellas Pharma, Inc., Tokyo, Japan. 3. Japan-Asia Clinical Development 2, Development, Astellas Pharma, Inc., Tokyo, Japan. 4. Therapeutic Area Medical Specialties, Astellas Pharma Europe B.V., Leiden, The Netherlands.
Abstract
INTRODUCTION: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved for the treatment of anemia in Japan for patients with dialysis-dependent (DD) chronic kidney disease (CKD). OBJECTIVE: Multicenter, randomized, open-label, noncomparative, phase 3 study to evaluate roxadustat for anemia of non-dialysis-dependent (NDD) CKD in Japan. METHODS: Erythropoiesis stimulating agent (ESA)-naïve NDD-CKD patients were randomized to roxadustat (initial dose, 50 or 70 mg 3 times weekly), titrated to maintain hemoglobin (Hb) within 10.0-12.0 g/dL, for ≤24 weeks. Patients with either transferrin saturation of ≥5% or serum ferritin of ≥30 ng/mL during the screening period were eligible. Endpoints included response rate (proportion of patients achieving Hb ≥10.0 or ≥10.5 g/dL and Hb increase ≥1.0 g/dL from baseline) at end of treatment; average Hb (weeks 18-24); change of average Hb from baseline to weeks 18-24; maintenance rate (proportion of patients achieving Hb 10.0-12.0 g/dL at weeks 18-24); rate of rise (RoR) of Hb from weeks 0-4, discontinuation, or dose adjustment. Adverse events were monitored throughout the study. RESULTS: Of 135 patients who provided informed consent, 100 were randomized and 99 received roxadustat (50 mg, n = 49; 70 mg, n = 50). The mean (SD) dose of roxadustat per intake at week 22 was 36.3 (22.7) mg in the roxadustat 50 mg group and 36.8 (16.0) mg in the roxadustat 70 mg group. Prior medications included oral iron therapy (20.2%) and intravenous iron therapy (1.0%). Overall response rate (95% CI) was 97.0% (91.4, 99.4; Hb ≥10.0 g/dL) and 94.9% (88.6, 98.3; Hb ≥10.5 g/dL). Mean (SD) Hb (weeks 18-24) was 11.17 (0.62) g/dL. Mean (SD) change of Hb from baseline (weeks 18-24) was 1.34 (0.86) g/dL. Maintenance rate (95% CI) was 88.8% (80.3, 94.5) among patients with ≥1 Hb measurement during weeks 18-24. Mean (SD) RoR of Hb was 0.291 (0.197) g/dL/week (50 mg) and 0.373 (0.235) g/dL/week (70 mg). Nasopharyngitis and hypertension were the most common adverse events. CONCLUSION: Roxadustat increased and maintained Hb in ESA-naïve, partially iron-depleted NDD-CKD patients with anemia.
INTRODUCTION: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved for the treatment of anemia in Japan for patients with dialysis-dependent (DD) chronic kidney disease (CKD). OBJECTIVE: Multicenter, randomized, open-label, noncomparative, phase 3 study to evaluate roxadustat for anemia of non-dialysis-dependent (NDD) CKD in Japan. METHODS: Erythropoiesis stimulating agent (ESA)-naïve NDD-CKD patients were randomized to roxadustat (initial dose, 50 or 70 mg 3 times weekly), titrated to maintain hemoglobin (Hb) within 10.0-12.0 g/dL, for ≤24 weeks. Patients with either transferrin saturation of ≥5% or serum ferritin of ≥30 ng/mL during the screening period were eligible. Endpoints included response rate (proportion of patients achieving Hb ≥10.0 or ≥10.5 g/dL and Hb increase ≥1.0 g/dL from baseline) at end of treatment; average Hb (weeks 18-24); change of average Hb from baseline to weeks 18-24; maintenance rate (proportion of patients achieving Hb 10.0-12.0 g/dL at weeks 18-24); rate of rise (RoR) of Hb from weeks 0-4, discontinuation, or dose adjustment. Adverse events were monitored throughout the study. RESULTS: Of 135 patients who provided informed consent, 100 were randomized and 99 received roxadustat (50 mg, n = 49; 70 mg, n = 50). The mean (SD) dose of roxadustat per intake at week 22 was 36.3 (22.7) mg in the roxadustat 50 mg group and 36.8 (16.0) mg in the roxadustat 70 mg group. Prior medications included oral iron therapy (20.2%) and intravenous iron therapy (1.0%). Overall response rate (95% CI) was 97.0% (91.4, 99.4; Hb ≥10.0 g/dL) and 94.9% (88.6, 98.3; Hb ≥10.5 g/dL). Mean (SD) Hb (weeks 18-24) was 11.17 (0.62) g/dL. Mean (SD) change of Hb from baseline (weeks 18-24) was 1.34 (0.86) g/dL. Maintenance rate (95% CI) was 88.8% (80.3, 94.5) among patients with ≥1 Hb measurement during weeks 18-24. Mean (SD) RoR of Hb was 0.291 (0.197) g/dL/week (50 mg) and 0.373 (0.235) g/dL/week (70 mg). Nasopharyngitis and hypertension were the most common adverse events. CONCLUSION: Roxadustat increased and maintained Hb in ESA-naïve, partially iron-depleted NDD-CKD patients with anemia.
Authors: Anatole Besarab; Elena Chernyavskaya; Igor Motylev; Evgeny Shutov; Lalathaksha M Kumbar; Konstantin Gurevich; Daniel Tak Mao Chan; Robert Leong; Lona Poole; Ming Zhong; Khalil G Saikali; Marietta Franco; Stefan Hemmerich; Kin-Hung Peony Yu; Thomas B Neff Journal: J Am Soc Nephrol Date: 2015-10-22 Impact factor: 10.121
Authors: Anatole Besarab; Robert Provenzano; Joachim Hertel; Raja Zabaneh; Stephen J Klaus; Tyson Lee; Robert Leong; Stefan Hemmerich; Kin-Hung Peony Yu; Thomas B Neff Journal: Nephrol Dial Transplant Date: 2015-08-03 Impact factor: 5.992
Authors: Patrizia Natale; Suetonia C Palmer; Allison Jaure; Elisabeth M Hodson; Marinella Ruospo; Tess E Cooper; Deirdre Hahn; Valeria M Saglimbene; Jonathan C Craig; Giovanni Fm Strippoli Journal: Cochrane Database Syst Rev Date: 2022-08-25
Authors: Pablo E Pergola; Chaim Charytan; Dustin J Little; Stefan Tham; Lynda Szczech; Robert Leong; Steven Fishbane Journal: Kidney360 Date: 2022-06-29
Authors: Daniel W Coyne; Simon D Roger; Sug Kyun Shin; Sung Gyun Kim; Andres A Cadena; Moustafa A Moustafa; Tak Mao Chan; Anatole Besarab; Willis Chou; Charles Bradley; Meraf Eyassu; Robert Leong; Tyson T Lee; Khalil G Saikali; Lynda Szczech; Kin-Hung P Yu Journal: Kidney Int Rep Date: 2020-12-05
Authors: Steven Fishbane; Mohamed A El-Shahawy; Roberto Pecoits-Filho; Bui Pham Van; Mark T Houser; Lars Frison; Dustin J Little; Nicolas J Guzman; Pablo E Pergola Journal: J Am Soc Nephrol Date: 2021-02-10 Impact factor: 10.121
Authors: Robert Provenzano; Lynda Szczech; Robert Leong; Khalil G Saikali; Ming Zhong; Tyson T Lee; Dustin J Little; Mark T Houser; Lars Frison; John Houghton; Thomas B Neff Journal: Clin J Am Soc Nephrol Date: 2021-08 Impact factor: 10.614